Sorbon

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sorbon

Quick Facts

Attribute Detail
Active Ingredient Buspirone hydrochloride
Therapeutic Class Anxiolytic (Anti-anxiety agent)
Primary Use Management of Generalized Anxiety Disorder (GAD)
Controlled Status Not a federally controlled substance in the US

Sorbon is a brand name for the prescription medication buspirone hydrochloride, which belongs to a class of drugs known as anxiolytics, or anti-anxiety agents. It is primarily indicated for the management of anxiety disorders, particularly Generalized Anxiety Disorder (GAD), or for the short-term relief of anxiety symptoms.

Unlike benzodiazepines, buspirone's mechanism of action is distinct, as it is not chemically or pharmacologically related to them. Its effects are believed to be mediated by its high affinity for certain serotonin (5-HT) and dopamine receptors in the brain. This unique mechanism means that, in clinical studies, buspirone generally does not exhibit the same risk of dependence or significant sedation associated with many other anxiety medications. However, the full anti-anxiety benefit of Sorbon is typically not immediate and may require two to four weeks of consistent use to become fully apparent. Sorbon is available as an oral tablet and is generally not intended for use in individuals under the age of 18.

Regulatory References

  1. require two to four weeks of consistent use

What side effects are possible with Sorbon?

Adverse Reactions and Safety Profile for Sorbon

Official regulatory documentation, such as those issued by the FDA or EMA, classifies all documented adverse effects of Sorbon to ensure clarity and consistency in safety reporting. Adverse Drug Reactions (ADRs) are defined as harmful and unintended responses where a causal relationship with the drug is considered at least a reasonable possibility.

ADRs are systematically categorized by System Organ Class (SOC) and by frequency using internationally recognized bands:

  • Very Common: 1/10 (10% or more)
  • Common: 1/100 to < 1/10 (1% to < 10%)
  • Uncommon: 1/1,000 to < 1/100 (0.1% to < 1%)
  • Rare: 1/10,000 to < 1/1,000 (0.01% to < 0.1%)
  • Very Rare: < 1/10,000 (less than 0.01%)

Serious and Clinically Significant Safety Information

Serious Adverse Events (SAEs) are those that result in specific outcomes, including death, life-threatening conditions, hospitalization, persistent disability, or a congenital anomaly. Reactions are further classified as Type A (Augmented), which are dose-dependent and expected exaggerations of the drug's known action, or Type B (Bizarre), which are unpredictable, non-dose-related, and novel responses. Safety monitoring focuses on detecting any unexpected shift in the frequency or severity of these events.


Population-Specific Notes

Official safety documents mandate specific consideration for special populations, including pediatric, geriatric, and those with hepatic or renal impairment, as these groups may experience altered safety profiles. The labeling also includes safety-related restrictions, such as formal contraindications (situations where the drug must not be used) and requirements for the follow-up of exposure in situations like pregnancy, overdose, or medication error.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documentation on Sorbon (buspirone hydrochloride) overdosage describes specific clinical signs and mandates immediate emergency action. The symptoms listed are primarily an exaggeration of the medication's pharmacological effects, focusing on the Central Nervous System (CNS) and the gastrointestinal system.

Documented Overdose Manifestations

Clinical signs include dizziness, lightheadedness, and severe drowsiness (somnolence). Gastrointestinal effects often involve nausea and vomiting. In more severe cases, the documentation notes the possibility of loss of consciousness. A critical, regulator-recognized risk is the development of Serotonin Syndrome, particularly when the drug is taken with other serotonergic agents. Patients with pre-existing kidney or liver disease may be at risk for exaggerated effects due to slower clearance, which is a population-specific consideration.

Emergency Actions and Management

Regulatory guidance mandates that immediate medical attention must be sought for any suspected overdosage. Management is symptomatic and supportive, as no specific antidote is known for buspirone. Procedural steps described in the labeling include immediate gastric lavage and the administration of activated charcoal in appropriate settings. During supportive care, continuous monitoring of respiration, pulse, and blood pressure is required.

Therapeutic Uses of Sorbon

What Sorbon Treats: Main Uses and Benefits

Sorbon is commonly used for the sustained management of Generalized Anxiety Disorder (GAD). It is relevant for easing feelings of persistent worry and mental tension, which are key manifestations of this chronic condition, and may support the maintenance of a sense of stability during sustained treatment periods.

It is often applied in clinical settings to address symptoms of anxiety, including excessive worry, restlessness, irritability, and muscle tension. Quick Fact: Relief for Chronic Mental Tension

The medication is used for managing symptoms that interfere with daily functioning and accompany chronic anxiety. It may assist in easing physical manifestations such as muscle tension and restlessness, which are often secondary to persistent worry, and may contribute to improved day-to-day comfort. Sorbon provides supportive relief and is relevant in contexts involving a treatment option with a distinct profile. This profile is considered relevant in situations where this factor is prioritized.

“It is a medication applied in addressing symptoms related to persistent, generalized worry.”

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Sorbon (buspirone) is indicated for use in adults 18 years of age and older for the management of Generalized Anxiety Disorder (GAD). Official regulatory documents strictly define the populations permitted to use the medicine, as well as those for whom use is prohibited or restricted.

Classification Population Group/Condition
Contraindicated Patients with known hypersensitivity to buspirone hydrochloride.
Contraindicated Patients currently using or having recently discontinued a Monoamine Oxidase Inhibitor (MAOI), including linezolid and intravenous methylene blue.
Not Recommended Pediatric patients (under 18 years old), as safety and effectiveness have not been established.
Not Recommended Patients with severe hepatic insufficiency or severe renal insufficiency (e.g., creatinine clearance <20 mL/min/1.73 m^2), per international labeling.
Conditional Use Patients with non-severe hepatic or renal impairment require caution and may necessitate dose adjustment due to increased drug exposure.
Conditional Use Use during pregnancy or lactation should be considered only if clearly needed, with caution advised due to limited human data.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interaction Scope

Attribute Detail
Medicinal product categories with documented interactions Monoamine Oxidase Inhibitors (MAOIs), Potent CYP3A4 Inhibitors, Potent CYP3A4 Inducers, Other Serotonergic Drugs, Central Nervous System (CNS) Depressants.
Specific interacting medicines (if explicitly listed) Itraconazole, Erythromycin, Rifampin, Diltiazem, Verapamil, Nefazodone, Linezolid, Haloperidol, Warfarin, Cimetidine.
Mechanistic basis of interactions (only if stated in label) Inhibition or induction of Cytochrome P450 3A4 (CYP3A4)-mediated metabolism, resulting in significant changes in buspirone plasma concentrations (AUC/Cmax). Additive pharmacodynamic effects on the serotonergic system (risk of serotonin syndrome) and CNS depression.
Timing-based interaction rules (if applicable) Co-administration with an MAOI is not recommended; a 14-day washout period is required when switching from or to an MAOI therapy.
Population-specific interaction notes (if applicable) Hepatic Impairment: Buspirone exposure increased approximately 13-fold. Renal Impairment: Buspirone exposure increased approximately 4-fold. Use is contraindicated/not recommended in patients with severe hepatic or renal impairment.
Interaction-related restrictions Concomitant use with MAOIs is not recommended due to the risk of serotonin syndrome and hypertensive reaction. Consumption of large quantities of grapefruit juice must be avoided due to the documented increase in plasma concentrations.

Interaction Classifications (High-Level)

Attribute Detail
Interaction severity classification (as defined in official documents) Contraindicated/Not Recommended: MAOIs. Clinically Significant Exposure Change: Potent CYP3A4 Inhibitors (e.g., Itraconazole causes AUC uparrow 19-fold) and CYP3A4 Inducers (e.g., Rifampin causes AUC downarrow 90%).
Regulatory basis (EMA / FDA / etc.) Interaction information is documented in official prescribing information such as FDA Prescribing Information and EMA/national SmPC documents.
Interaction-context constraints (as defined in official documents) Must be taken consistently relative to food intake (always with food or always without) to maintain consistent systemic exposure.

Resulting Interaction Structure

The official interaction statements classify combinations primarily based on metabolic interference via the CYP3A4 enzyme and pharmacodynamic effects on the serotonergic and central nervous systems. The profile establishes mandatory restrictions on co-administration with MAOIs and large amounts of grapefruit juice. Furthermore, population-specific warnings for hepatic and renal impairment define contexts where drug exposure is significantly increased, requiring caution in severe cases.

Mechanism of Action

Targeted Modulation of the Serotonergic System

Sorbon acts primarily as a partial agonist at the serotonin mathbf5- HT1A receptors and exhibits weak antagonism at dopamine mathbf D2 receptors. The key mechanism involves the mathbf5- HT1A partial agonism, which is exerted both pre-synaptically on autoreceptors and post-synaptically in the limbic system. At the cellular level, activation of the 5- HT1A receptor initiates a Gi/ Go protein-mediated cascade** that influences neuronal excitability by promoting the opening of K^+ channels and subsequent hyperpolarization.

Time-Dependent Cellular Adaptation

The full physiological effect of the mechanism is dependent on a process of cellular adjustment. Specifically, the acute binding to presynaptic mathbf5- HT1A autoreceptors initially inhibits serotonin release. Over weeks, these autoreceptors undergo desensitization and down-regulation, which functionally removes the inhibitory influence. This adaptation leads to a sustained increase in functional serotonin signaling and contributes to the establishment of a regulated physiological state. The mechanism lacks interaction with the GABAA receptor, differentiating its physiological effects from those that cause generalized central nervous system suppression.

Dosage and Administration Information

Official Administration Protocol

Sorbon is approved exclusively for oral administration as a tablet. The protocol mandates a highly structured dosing regimen to establish the correct therapeutic level, which is achieved through a gradual titration process. The usual adult starting dose is 15 mg per day, administered in two or three divided doses to maintain consistent levels of the active substance. Following initiation, the total daily dosage may be titrated by increasing the amount by 5 mg per day every two to three days. The typical adult maintenance dose is generally in the range of 20 mg to 30 mg daily, and the total amount administered in any 24-hour period should not exceed the official maximum dose of 60 mg.

A key procedural requirement for administration is maintaining a consistent relationship to food. The medicine must always be taken either with food or without food for every dose to ensure predictable absorption and stable blood levels. The tablets are scored, which allows for precise division to facilitate the necessary incremental dose adjustments during titration. If a regular dose is missed, the user is instructed to take the next scheduled dose at the normal time, without doubling the amount to compensate.

Special procedural conditions apply to specific patient groups: the medicine is not recommended for individuals with severe renal or hepatic impairment, and caution is necessary for mild-to-moderate impairment. For treatment extending beyond the initial period, periodic reassessment of the need for continuation is required as part of the overall usage protocol.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Sorbon


Evidence for use in Adults with Chronic Primary Insomnia

Sorbon was studied for use in adults who experience chronic primary insomnia, a condition characterized by functional limitations related to getting to sleep and staying asleep. The research explored how the medicine was evaluated against outcomes reflecting daily functioning, such as sleep continuity. Studies typically monitored these changes over defined time intervals, often in a controlled research setting.

Research highlights changes measured during the study period in terms of time taken to fall asleep and total time spent sleeping. Findings describe group patterns, not personal outcomes, and research does not determine whether an individual will respond similarly. Comparative evidence is lacking to completely show how Sorbon's measured changes compare against all other existing treatments. Long-term effects are not fully established, and certainty remains low regarding its use beyond the studied duration.


Evidence for use in Older Adults with Age-Related Sleep Disturbances

Sorbon was evaluated in a subgroup of older adults with sleep patterns often associated with aging. This is a special population because age may affect how the body processes medicine. Data show patterns related to certain changes in sleep patterns that were observed in some older adults. These findings help contextualize how patients reported their experience of sleep quality during the study period.

However, the sample sizes were modest in some analyses, meaning the results apply only to the populations studied. Evidence is limited for individuals who have multiple co-existing health issues. Therefore, subgroup findings are uncertain, and further research is needed to more completely understand the further data needed for using Sorbon in the full range of the older adult population.


What is Still Uncertain About Sorbon

This section outlines the main evidence gaps and areas where more research is needed. While research provides insight into short-term changes, more studies are needed to understand the consequences of using Sorbon intermittently versus continuously. Comparative evidence is lacking to fully understand how Sorbon's profile compares to the full range of other available sleep treatments.

The study results reflect the specific conditions under which they were conducted. This means that understanding how the observed patterns translate to a person's individual, daily-life setting may be uncertain. Finally, there remains a need for studies with larger and more diverse groups of participants to ensure the findings describe group patterns that are truly representative.

Key Studies & References Long-term use of benzodiazepines in chronic insomnia: a European perspective (Used to contextualize long-term evidence gaps and associated risks)

Frequently Asked Questions (FAQ)

Common questions about Sorbon (FAQ)


Q: What should I expect in the first few days of taking Sorbon?

Studies indicate that the full anti-anxiety benefit of Sorbon typically requires two to four weeks of consistent use to develop. In the initial phase of treatment, some common effects that may be noticed include headache, nausea, or dizziness. The medicine is started at a low amount and gradually increased as part of the official administration protocol.


Q: Are there any common foods or drinks that should be avoided when using Sorbon?

Official product information states that consuming large quantities of grapefruit or grapefruit juice is advised to be avoided. Grapefruit can interfere with the way the body processes Sorbon, which can increase the levels of the medicine in the bloodstream, leading to higher levels than intended.


Q: Do I need to take Sorbon at a specific time of day?

Sorbon is typically prescribed as a total daily dose divided into two or three administrations. Official guidance emphasizes that consistency is key: each dose is typically advised to be taken the same way—either always with food or always without food—to maintain stable drug levels.


Q: How long is Sorbon usually taken for?

Official regulatory information indicates that controlled clinical studies demonstrating the effectiveness of Sorbon have not extended beyond three to four weeks. Due to this evidence profile, official guidance recommends periodic reassessment by a professional to determine the continued need for the medicine.


Q: What are the most commonly reported side effects of Sorbon?

Based on official reports, very common side effects reported by 10% or more of patients include dizziness and headache. Other common effects, reported by 1% to 10% of patients, may include nervousness, nausea, dry mouth, and fatigue.


Q: What does 'contraindication' mean in relation to Sorbon?

A contraindication is a circumstance where a medicine must not be used because the risks involved outweigh any potential benefit. For Sorbon, regulatory documents specify that use is contraindicated in patients with a known hypersensitivity or those currently taking, or who have recently taken, a Monoamine Oxidase Inhibitor (MAOI).


Q: What is the difference between Sorbon's active ingredient and inactive ingredients?

Sorbon's active ingredient, buspirone hydrochloride, is the substance responsible for the medicine's therapeutic effect. Inactive ingredients, such as lactose monohydrate and coloring, are added to help form the tablet but do not contribute to the primary therapeutic action of the drug.


Q: Why is Sorbon sometimes preferred over other treatment options?

Official product information highlights that Sorbon is structurally distinct from certain other anxiety medicines, such as benzodiazepines. This unique profile means that it generally lacks the same prominent central nervous system depressant effects or significant risk of dependence.


Q: Does Sorbon require a special prescription or monitoring?

Official prescribing information mandates that the need for continued treatment must be periodically reassessed. Because Sorbon is processed by the liver and kidneys, official guidance suggests monitoring of these organ functions may be warranted, particularly for individuals with existing impairment.


Q: What are the signs of a serious, but rare, side effect of Sorbon?

Serious adverse events are reported rarely. Examples include symptoms of Serotonin Syndrome, such as agitation, fever, or a fast heart rate. Involuntary movement problems (dyskinesia) and chest pain have also been reported in rare instances.


Q: Is there a maximum time frame for how long a person can be on Sorbon?

Official clinical data supporting the effectiveness of Sorbon in controlled studies does not extend beyond a period of three to four weeks. Official guidance recommends that the need for continuation of the medicine should be periodically reassessed, rather than setting a fixed maximum duration.


Q: What other common medications are listed as having a potential interaction with Sorbon?

Official interaction statements classify combinations primarily based on metabolic interference via the CYP3A4 enzyme. Medications that strongly inhibit this enzyme, such as certain antibiotics or heart medications, as well as other serotonergic drugs, have the potential to interact.


Q: Can Sorbon affect my ability to drive?

Regulatory warnings state that Sorbon may affect alertness or coordination in some individuals. Regulatory warnings suggest that operating complex machinery or driving is generally advised to be avoided until an individual understands how the medicine affects them.


Q: Are there different versions or forms of Sorbon available?

Sorbon is primarily available in the form of an oral tablet. Official product information notes that the tablets are scored, which allows them to be divided.


Q: Is hair loss a possible side effect of Sorbon?

Official product labeling lists hair loss, known medically as alopecia, as an infrequent adverse reaction. This means it is reported in less than 1% of patients in clinical studies.


Q: Does Sorbon cause weight gain or weight loss?

Regulatory documents list both weight gain and weight loss as infrequent adverse events. Both effects were reported in less than 1% of patients during clinical trials.


Q: Can Sorbon interact with vitamins or herbal supplements?

Official prescribing information states that individuals should inform their healthcare provider about all prescription and non-prescription products, including vitamins and herbal supplements. Certain supplements may affect how Sorbon is metabolized by the body or could increase central nervous system activity.


Q: Is it necessary to have certain tests before starting Sorbon?

While routine testing is not universally mandated, official precautions state that monitoring of liver or kidney function may be warranted. This is especially true for patients with known impairment, as these organs are vital for processing the medicine.


Q: How is Sorbon eliminated from the body?

According to official clinical pharmacology information, Sorbon is rapidly metabolized and then eliminated primarily through the kidneys. Because of this, kidney problems can cause the drug to build up in the body.


Q: Is it normal to feel a little dizzy when first taking Sorbon?

Dizziness is listed in the official documents as a very common side effect, meaning it is reported by 10% or more of patients. It is one of the more frequently reported reactions, particularly during the initial phase of treatment.


Q: Can Sorbon be used by people with a history of heart problems?

Official adverse event reports indicate that rare cardiovascular issues, such as chest pain, rapid heart rate (tachycardia), and blood pressure changes, have been reported. As with any medicine affecting the central nervous system, caution is advised.


Q: What are the known potential interactions between Sorbon and alcohol?

Regulatory warnings advise that the concurrent use of Sorbon and alcohol is generally restricted. Alcohol may increase nervous system side effects of Sorbon, such as drowsiness, dizziness, and difficulty concentrating.


Q: Will Sorbon affect my ability to get pregnant?

Studies and official information indicate that it is not known if Sorbon can affect a person’s ability to conceive. While animal studies have not shown adverse effects on fertility, human data on this specific matter is currently limited.


Q: Does Sorbon contain any known allergens like gluten or lactose?

Official product descriptions confirm that Sorbon tablets contain lactose monohydrate as an inactive ingredient. The labeling does not provide specific information regarding the presence of gluten.


Q: Is it true that Sorbon can cause changes in mood?

Official adverse reaction reports list changes in mood as common effects. These include nervousness, excitement, and confusion, while depression and episodes of anger or hostility have also been reported.


Q: How soon after stopping Sorbon do the effects wear off?

According to official clinical data, the unchanged drug is cleared relatively quickly from the body, with a short average elimination half-life of about 2 to 3 hours. This indicates the time it takes for the concentration of the medicine to be reduced by half.


Q: Can I take Sorbon if I am also taking medicine for high blood pressure?

Some heart and blood pressure medicines, specifically those that inhibit the CYP3A4 enzyme, like diltiazem and verapamil, are known to interact by altering how Sorbon is metabolized. Any co-administration with such medicines is stated to require close monitoring by a professional.


Q: Is it true that Sorbon can cause problems with eyesight?

Official adverse reaction reports list blurred vision as a common side effect. There have also been rare reports of other visual changes, including a loss of peripheral vision, known as tunnel vision.


Q: What does the patient information leaflet say about stopping Sorbon?

Regulatory warnings suggest that stopping Sorbon suddenly is not recommended. A gradual dose reduction may be necessary to minimize potential symptoms that can occur upon discontinuation, such as increased anxiety or dizziness.

How should Sorbon be stored and disposed of?

How to Store and Dispose of Sorbon (Buspirone Hydrochloride)

Official Storage Requirements

Sorbon tablets must be stored at Controlled Room Temperature (CRT), specifically between 20 C to 25 C (68 F to 77 F). The product must be protected from light and dispensed in a tight, light-resistant container. Temperatures should not exceed 30 C (86 F).

It is mandatory to keep this medicine out of the sight and reach of children to prevent accidental ingestion.

Disposal Instructions

Sorbon is not listed on the FDA's flush list. Unused or expired tablets should be returned to a drug take-back program whenever possible. If a take-back option is unavailable, the medication can be mixed with an undesirable substance (such as dirt or coffee grounds), placed into a sealed container, and discarded in the household trash. Disposal must be conducted in accordance with local regulations, and the active ingredient should not be discarded into the water system or drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sorbon found in:

A-Z Index: